Reuters exclusively reported Jan. 1 that drugmakers including Pfizer, GlaxoSmithKline and Sanofi raised the list prices on more than 200 drugs. Later in the day, Bristol-Myers Squibb, Gilead Sciences and Biogen increased list prices of about 50 drugs.
The median price increase was about 5 percent, and nearly all of the price increases were below 10 percent.
Many branded drugmakers pledged to keep their U.S. list price hikes below 10 percent a year following backlash from lawmakers and the public.
More articles on pharmacy:
Amazon’s PillPack seeking to win over new insurers in 2020
Roche buys international rights to Sarepta’s Duchenne drug for $750M
Former Aegerion sales rep defrauded insurers, stole identities to push cholesterol drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
